San Diego Life Sciences Roundup: Regulus, Ocera, Lithera, and More

7/18/13Follow @bvbigelow

(Page 2 of 2)

its legal status as a public company. MediStem stopped issuing regular financial reports in 2009, saying it was focusing its resources on ERC-124, a universal donor stem cell product. In a statement, MediStem says endometrial regenerative cells possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, and other types of tissue.

—Following recent agreements with Janssen Pharmaceuticals and Bristol-Myers Squibb, The Scripps Research Institute announced a partnership with Sigma-Aldrich (NASDAQ: SIAL) that gives the St. Louis, MO-based life sciences conglomerate faster access to discoveries for the synthesis and analysis of potential drugs. Under the agreement, the institute gets funding to expand its basic research and development of novel reagents from laboratories led by professors Phil Baran, Jin-Quan Yu, Benjamin Cravatt, Carlos Barbas, Phillip Dawson, and Nobel Laureate K. Barry Sharpless. Sigma-Aldrich is a leading supplier of laboratory reagents, diagnostics, and other supplies for the scientific community.

Sapphire Energy, the San Diego industrial biotech developing technology to produce crude oil from algae, said it is expanding its partnership with The Linde Group of Munich, Germany, to commercialize its production of “green crude.” In addition to expanding the hydrothermal treatment process Sapphire developed, they will jointly license and market the technology into an expanded list of industries, including algae, municipal solid waste, and farm waste. Their five-year agreement extends development of Sapphire Energy’s first commercial scale, algae-to-energy production facility.

—San Diego’s Abide Therapeutics said it has identified an enzyme in the serine hydrolase family as a therapeutic target to slow and potentially reverse the effects of Alzheimer’s disease. Abide has created a proprietary platform that specifically targets serine hydrolases with selective small molecules. The Cure Alzheimer’s Fund has provided a grant to Abide and the UC San Diego School of Medicine to validate the new target, monoacylglycerol lipase (MAGL) for both Down syndrome and Alzheimer’s disease. Down syndrome is caused by chromosome 21 trisomy, which contains genes involved in Alzheimer’s disease.

—San Diego’s La Jolla Pharmaceutical said the FDA has granted orphan drug status for its drug, galectin-3, for treating a genetic neurological disorder called Niemann-Pick type C disease. It is the second orphan designation for drugs under development at the company. “We remain dedicated to developing novel treatments to help those suffering with unmet debilitating and fatal diseases,” CEO George Tidmarsh” said in a statement.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.